Literature DB >> 21164535

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Julian G Hurdle1, Alex J O'Neill, Ian Chopra, Richard E Lee.   

Abstract

Persistent infections involving slow-growing or non-growing bacteria are hard to treat with antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need for antimicrobials that can treat infections containing dormant bacteria. In this Review, we discuss the emerging concept that disrupting the bacterial membrane bilayer or proteins that are integral to membrane function (including membrane potential and energy metabolism) in dormant bacteria is a strategy for treating persistent infections. The clinical applicability of these approaches is exemplified by the efficacy of lipoglycopeptides that damage bacterial membranes and of the diarylquinoline TMC207, which inhibits membrane-bound ATP synthase. Despite some drawbacks, membrane-active agents form an important new means of eradicating recalcitrant, non-growing bacteria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21164535      PMCID: PMC3496266          DOI: 10.1038/nrmicro2474

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  161 in total

1.  Anaerobic metabolism occurs in the substratum of gonococcal biofilms and may be sustained in part by nitric oxide.

Authors:  Megan L Falsetta; Alastair G McEwan; Michael P Jennings; Michael A Apicella
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

Review 2.  Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.

Authors:  Daniel J Hassett; John Cuppoletti; Bruce Trapnell; Sergei V Lymar; John J Rowe; Sang Sun Yoon; George M Hilliard; Kislay Parvatiyar; Moneesha C Kamani; Daniel J Wozniak; Sung Hei Hwang; Timothy R McDermott; Urs A Ochsner
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

3.  Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus.

Authors:  Diane Ordway; Miguel Viveiros; Clara Leandro; Maria Jorge Arroz; Leonard Amaral
Journal:  Int J Antimicrob Agents       Date:  2002-07       Impact factor: 5.283

4.  Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae.

Authors:  Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

5.  Susceptibility of Chlamydia trachomatis to protegrins and defensins.

Authors:  B Yasin; S S Harwig; R I Lehrer; E A Wagar
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections.

Authors:  Yanmin Hu; Alireza Shamaei-Tousi; Yingjun Liu; Anthony Coates
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

7.  Anti-staphylococcal activity and mode of action of clofazimine.

Authors:  Brunello Oliva; Alexander John O'Neill; Keith Miller; William Stubbings; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2004-02-04       Impact factor: 5.790

8.  Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors:  Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 10.  A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.

Authors:  Michael T Guskey; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2010-01       Impact factor: 4.705

View more
  216 in total

1.  Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations.

Authors:  Julian G Hurdle; Amy E Heathcott; Lei Yang; Bing Yan; Richard E Lee
Journal:  J Antimicrob Chemother       Date:  2011-05-31       Impact factor: 5.790

Review 2.  Small molecule control of bacterial biofilms.

Authors:  Roberta J Worthington; Justin J Richards; Christian Melander
Journal:  Org Biomol Chem       Date:  2012-10-07       Impact factor: 3.876

3.  Problem of persisters persists, but anti-cancer drugs hold hope.

Authors:  Boer Deng
Journal:  Nat Med       Date:  2015-08       Impact factor: 53.440

4.  In vitro evaluation of a multispecies oral biofilm over antibacterial coated titanium surfaces.

Authors:  Javi Vilarrasa; Luis M Delgado; Marta Galofré; Gerard Àlvarez; Deborah Violant; José María Manero; Vanessa Blanc; F Javier Gil; José Nart
Journal:  J Mater Sci Mater Med       Date:  2018-11-03       Impact factor: 3.896

5.  Predicting the in vivo mechanism of action for drug leads using NMR metabolomics.

Authors:  Steven Halouska; Robert J Fenton; Raúl G Barletta; Robert Powers
Journal:  ACS Chem Biol       Date:  2011-12-01       Impact factor: 5.100

Review 6.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

7.  Natural products as inspiration for the development of bacterial antibiofilm agents.

Authors:  Roberta J Melander; Akash K Basak; Christian Melander
Journal:  Nat Prod Rep       Date:  2020-07-01       Impact factor: 13.423

8.  Structure-activity studies of divin: an inhibitor of bacterial cell division.

Authors:  Maoquan Zhou; Ye-Jin Eun; Ilia A Guzei; Douglas B Weibel
Journal:  ACS Med Chem Lett       Date:  2013-09-12       Impact factor: 4.345

9.  Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead.

Authors:  Dianqing Sun; Julian G Hurdle; Robin Lee; Richard Lee; Mark Cushman; John M Pezzuto
Journal:  ChemMedChem       Date:  2012-07-30       Impact factor: 3.466

10.  Inhibitors of bacterial tubulin target bacterial membranes in vivo.

Authors:  Marie H Foss; Ye-Jin Eun; Charles I Grove; Daniel A Pauw; Nohemy A Sorto; Jarred W Rensvold; David J Pagliarini; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2012-07-18       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.